Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed prostate cancer
• •Stratum 1 (androgen ablation therapy):
• •* Bone metastases
• •* Prior orchiectomy allowed
• •* Prior or concurrent leuprolide and/or goserelin therapy allowed
• •Stratum 2 (androgen ablation therapy):
• •* No bone metastases
• •* Prior orchiectomy allowed
• •* Prior or concurrent leuprolide and/or goserelin therapy allowed
• •Stratum 3 (no androgen ablation therapy):
• •* No metastatic disease
• •* Prior flutamide or bicalutamide therapy allowed
• •PATIENT CHARACTERISTICS:
• •Age:
• •Not specified
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Calcium normal
• •Hepatic:
• •Not specified
• •Renal:
• •Not specified
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •See Disease Characteristics
• •Endocrine therapy:
• •See Disease Characteristics
• •No concurrent high dose steroids
• •Radiotherapy:
• •Prior radiotherapy allowed
• •Surgery:
• •See Disease Characteristics
• •Prior radical prostatectomy allowed
• •Other:
• •No concurrent bisphosphonates